NZ585086A - Tetrahydroquinoline derivatives for treating post-traumatic stress disorders - Google Patents

Tetrahydroquinoline derivatives for treating post-traumatic stress disorders

Info

Publication number
NZ585086A
NZ585086A NZ585086A NZ58508608A NZ585086A NZ 585086 A NZ585086 A NZ 585086A NZ 585086 A NZ585086 A NZ 585086A NZ 58508608 A NZ58508608 A NZ 58508608A NZ 585086 A NZ585086 A NZ 585086A
Authority
NZ
New Zealand
Prior art keywords
formula
phenyl
pharmaceutically acceptable
compound
alkyl
Prior art date
Application number
NZ585086A
Other languages
English (en)
Inventor
Francois Jenck
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40467356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ585086(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of NZ585086A publication Critical patent/NZ585086A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ585086A 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders NZ585086A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2007054130 2007-10-10
PCT/IB2008/054138 WO2009047723A2 (en) 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders

Publications (1)

Publication Number Publication Date
NZ585086A true NZ585086A (en) 2012-03-30

Family

ID=40467356

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ585086A NZ585086A (en) 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders

Country Status (27)

Country Link
US (1) US9532985B2 (enExample)
EP (1) EP2207550B1 (enExample)
JP (1) JP5883222B2 (enExample)
KR (1) KR101733247B1 (enExample)
CN (1) CN101820878B (enExample)
AR (1) AR068768A1 (enExample)
AU (1) AU2008309194B2 (enExample)
BR (1) BRPI0818617A2 (enExample)
CA (1) CA2699504C (enExample)
CY (1) CY1114799T1 (enExample)
DK (1) DK2207550T3 (enExample)
EA (1) EA017443B1 (enExample)
ES (1) ES2444418T3 (enExample)
HR (1) HRP20140214T1 (enExample)
IL (1) IL204838A (enExample)
MA (1) MA31800B1 (enExample)
MX (1) MX2010003711A (enExample)
MY (1) MY153044A (enExample)
NZ (1) NZ585086A (enExample)
PE (1) PE20091010A1 (enExample)
PL (1) PL2207550T3 (enExample)
PT (1) PT2207550E (enExample)
SI (1) SI2207550T1 (enExample)
TW (1) TWI428129B (enExample)
UA (1) UA99150C2 (enExample)
WO (1) WO2009047723A2 (enExample)
ZA (1) ZA201003251B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007337659A1 (en) 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
KR20110036069A (ko) 2008-06-25 2011-04-06 액테리온 파마슈티칼 리미티드 5,6,7,8-테트라히드로-이미다조[1,5-ａ]피라진 화합물
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist
EP2608787B1 (en) 2010-08-24 2019-11-20 Idorsia Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
RU2571414C2 (ru) 2010-09-22 2015-12-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Циклопропановые соединения
EP2638008B1 (en) 2010-11-10 2015-07-01 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
WO2012085857A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides
ES2541531T3 (es) 2011-02-18 2015-07-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirazol e imidazol útiles como antagonistas de orexina
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
SI2776430T1 (sl) 2011-11-08 2016-06-30 Actelion Pharmaceuticals Ltd. 2-(1,2,3-triazol-2-il)benzamidni in 3-(1,2,3-triazol-2-il)pikolinamidni derivati kot antagonisti oreksinskega receptorja
DK2855453T3 (en) 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives
BR112015007516A2 (pt) 2012-10-10 2017-07-04 Actelion Pharmaceuticals Ltd antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
CN105793257B (zh) 2013-12-03 2018-11-13 爱杜西亚药品有限公司 苯并咪唑环化合物的晶形及其用途
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
JP6659681B2 (ja) 2014-10-23 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症を治療するための組成物および方法
JP7179049B2 (ja) * 2017-08-01 2022-11-28 ベルゲン ファーマシューティカル、 エルエルシー オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020007977A1 (en) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd 7-trifluoromethyl-[1,4]diazepan derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
WO2023218023A1 (en) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234840T3 (es) 2000-03-14 2005-07-01 Actelion Pharmaceuticals Ltd. Derivados de 1,2,3,4- tetrahidroisoquinolina.
RU2345985C2 (ru) * 2003-03-26 2009-02-10 Актелион Фармасьютиклз Лтд. Производные тетрагидроизохинолилацетамида в качестве антагонистов орексинового рецептора
RU2378257C2 (ru) * 2004-03-01 2010-01-10 Актелион Фармасьютиклз Лтд Замещенные производные 1,2,3,4-тетрагидроизохинолина
US7501395B2 (en) * 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
EA015256B1 (ru) * 2006-03-15 2011-06-30 Актелион Фармасьютикалз Лтд. Производные тетрагидроизохинолина для повышения функции памяти
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist

Also Published As

Publication number Publication date
CA2699504C (en) 2015-11-24
ZA201003251B (en) 2011-07-27
IL204838A0 (en) 2010-11-30
EA201000557A1 (ru) 2010-10-29
AU2008309194A1 (en) 2009-04-16
WO2009047723A3 (en) 2009-05-28
ES2444418T3 (es) 2014-02-25
PT2207550E (pt) 2014-02-07
AR068768A1 (es) 2009-12-02
UA99150C2 (ru) 2012-07-25
CA2699504A1 (en) 2009-04-16
JP5883222B2 (ja) 2016-03-09
EA017443B1 (ru) 2012-12-28
CY1114799T1 (el) 2016-12-14
TWI428129B (zh) 2014-03-01
EP2207550B1 (en) 2013-12-11
MY153044A (en) 2014-12-31
MA31800B1 (fr) 2010-10-01
HK1145440A1 (en) 2011-04-21
US9532985B2 (en) 2017-01-03
PL2207550T3 (pl) 2014-05-30
KR101733247B1 (ko) 2017-05-08
AU2008309194B2 (en) 2013-10-03
DK2207550T3 (da) 2014-01-27
SI2207550T1 (sl) 2014-03-31
IL204838A (en) 2014-09-30
JP2011500550A (ja) 2011-01-06
HRP20140214T1 (hr) 2014-04-11
KR20100065203A (ko) 2010-06-15
WO2009047723A2 (en) 2009-04-16
TW200932231A (en) 2009-08-01
MX2010003711A (es) 2010-04-30
PE20091010A1 (es) 2009-08-08
US20100234420A1 (en) 2010-09-16
CN101820878B (zh) 2012-02-01
EP2207550A2 (en) 2010-07-21
CN101820878A (zh) 2010-09-01
BRPI0818617A2 (pt) 2015-04-07

Similar Documents

Publication Publication Date Title
CA2699504C (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
JP5582535B2 (ja) 点眼投与による神経疾患または精神神経疾患の治療または予防
US20100249164A1 (en) Modulation of sleep with nr2b receptor antagonists
WO2015106268A1 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
EP2156833A1 (en) Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
TWI243678B (en) A pharmaceutical composition for the treatment and/or prophylaxis of conditions characterized by altered bowel function and/or visceral pain in human or non-human mammals
MXPA00013033A (es) Sulfonamidas que contienen isoesteres n-heterociclicos para las enfermedades de la vision y la memoria.
US20120035207A1 (en) Use of GABAA Receptor Agonists for the Treatment of Hearing, Vestibular and Attention Disorders, Intention Tremor and Restless Leg Syndrome
UA123352C2 (uk) Застосування похідних піридазину для попередження або лікування атаксичного синдрому
JP2008542417A (ja) 進行性ミオクローヌスてんかんに特徴付けられる疾患の治療用ブリバラセタムの使用
IL262920A (en) A triangular combination of pure 5 – ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor agonists
IL262816A (en) Combination of pure 5 – ht6 receptor antagonists with nmda receptor agonist
HK1145440B (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
JP2007519733A (ja) アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
KR980008226A (ko) 시각기능장애의 예방 및 치료제
Sévoz-Couche et al. Antinociceptive effect of cardiopulmonary chemoreceptor and baroreceptor reflex activation in the rat
MXPA00013031A (es) Ureas y carbamatos de acidos carboxilicos n-heterociclicos e isoesteres, para las enfermedades de la vision y la memoria.
US20260076935A1 (en) Prevention and treatment of conditions using ethyl pyruvate
Alkozi et al. Improving melatonin delivery within the eye
JP2002522482A (ja) 視力及び記憶障害に対する多様な異種原子を有するヘテロサイクリック環化合物のカルボン酸及び同配体
WO2014172453A2 (en) Novel compositions useful in treating brain-related diseases or disorders and methods using same

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2016 BY DENNEMEYER + CO

Effective date: 20150917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2017 BY DENNEMEYER + CO

Effective date: 20160921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2018 BY DENNEMEYER + CO

Effective date: 20170926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2019 BY DENNEMEYER + CO

Effective date: 20180928

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2020 BY DENNEMEYER + CO.

Effective date: 20190920

ASS Change of ownership

Owner name: IDORSIA PHARMACEUTICALS LTD, CH

Effective date: 20200602

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2021 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20200928

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2022 BY DENNEMEYER + CO.

Effective date: 20210928

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2023 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20220926

LAPS Patent lapsed